Plain-English translation of NCT07634640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are studying how inflammation affects the heart in people with a specific type of heart failure called HFpEF (heart failure with preserved ejection fraction). This trial uses iron infusions combined with cardiac MRI scans to visualize and measure inflammation in the heart muscle. The goal is to better understand this condition and develop new ways to treat it.
Many people with this type of heart failure don't respond well to current treatments, and doctors don't fully understand the inflammation happening in their hearts. This study aims to use advanced imaging techniques to see inflammation more clearly, which could lead to better treatments in the future.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic for a baseline visit where you'll have a heart MRI scan and then receive an iron infusion on the same day. Three days later, you'll return for a second heart MRI scan, during which the iron from your infusion acts as a contrast agent to help the doctors see your heart tissue more clearly. The entire study involves these two visits spaced three days apart.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
University of Florida
Collaborators
American Heart Association
Enrollment target
~70 participants
Started
November 2023
Primary completion
May 2027
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ellen C Keeley, MD, MS
University of Florida
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.